These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 8370633

  • 1. Phase I/II study of pentoxifylline with zidovudine on HIV-1 growth in AIDS patients.
    Luke DR, McCreedy BJ, Sarnoski TP, Bookout JB, Johnston AM, Lell JE, Wiggan EB, Bell N, Limjuco RA, Guthrie KI.
    Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):343-50. PubMed ID: 8370633
    [Abstract] [Full Text] [Related]

  • 2. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D, Bagnarelli P, Gorin I, Katlama C, Pialoux G, Saimot G, Tubiana P, De Truchis P, Chauvin JP, Mills R, Rode R, Clementi M, Leibowitch J.
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [Abstract] [Full Text] [Related]

  • 3. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
    Godfried MH, van der Poll T, Mulder JW, Weverling GJ, Endert E, Lange JM, Sauerwein HP.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec 15; 10(5):531-9. PubMed ID: 8548332
    [Abstract] [Full Text] [Related]

  • 4. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec 15; 10 Suppl 1():S57. PubMed ID: 8595510
    [Abstract] [Full Text] [Related]

  • 5. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
    Ruiz L, Romeu J, Ibáñez A, Cabrera C, Puig T, Morales MA, Sirera G, Clotet B.
    Antivir Ther; 1996 Dec 15; 1(4):220-4. PubMed ID: 11324824
    [Abstract] [Full Text] [Related]

  • 6. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S, Lazzarin A, Carosi G, Sinicco A, Armignacco O, Angarano G, Andreoni M, Tambussi G, Chiodera A, Floridia M, Scaccabarozzi S, Facey K, Duncan I, Boudes P, Bragman K.
    Antivir Ther; 1996 Aug 15; 1(3):129-40. PubMed ID: 11322246
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068.
    Mildvan D, Bassiakos Y, Zucker ML, Hyslop N, Krown SE, Sacks HS, Zachary J, Paredes J, Fessel WJ, Rhame F, Kramer F, Fischl MA, Poiesz B, Wood K, Ruprecht RM, Kim J, Grossberg SE, Kasdan P, Bergé P, Marshak A, Pettinelli C.
    Antivir Ther; 1996 Apr 15; 1(2):77-88. PubMed ID: 11321183
    [Abstract] [Full Text] [Related]

  • 12. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1999 Feb 15; 469():1-361. PubMed ID: 12579204
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.